{"disease":{"id":"high-grade-squamous-intraepithelial-neoplasia","name":"high grade squamous intraepithelial neoplasia"},"drugs":{"marketed":[{"drug_id":"ipilimumab","indication_name":"High grade squamous intraepithelial neoplasia of esophagus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Yervoy","generic_name":"ipilimumab","company_name":"Bristol-Myers Squibb","drug_phase":"discontinued","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"CTLA-4-directed Blocking Antibody","quality_score":0,"revenue":"2900","mechanism":"Yervoy blocks a protein called CTLA-4, which normally helps to turn off the immune system, allowing it to attack cancer cells."},{"drug_id":"yervoy","indication_name":"High grade squamous intraepithelial neoplasia of esophagus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Yervoy","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"","quality_score":16,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05210348","title":"Clinical Evaluation of Detection of High Risk HPV in Urine","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Peking University People's Hospital","has_results":false},{"nct_id":"NCT03284866","title":"HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":536,"lead_sponsor_name":"AIDS Malignancy Consortium","has_results":false},{"nct_id":"NCT02140021","title":"Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer","phase":"NA","overall_status":"TERMINATED","enrollment_count":409,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03603808","title":"VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"AIDS Malignancy Consortium","has_results":false},{"nct_id":"NCT03180684","title":"Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":33,"lead_sponsor_name":"Inovio Pharmaceuticals","has_results":true},{"nct_id":"NCT04276935","title":"Development of a Health-Related Symptom Index for Participants With and Either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions","phase":"","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"AIDS Malignancy Consortium","has_results":true},{"nct_id":"NCT05104099","title":"Evaluation of New Diagnostic Tool Using Fluorescence to Detect High-grade Vulvar Intraepithelial Neoplasia","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"Institut de Cancérologie de Lorraine","has_results":false},{"nct_id":"NCT03239223","title":"Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Antiva Biosciences","has_results":false},{"nct_id":"NCT03697226","title":"Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection.","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"Antiva Biosciences","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}